" class="no-js "lang="en-US"> Musculoskeletal (MSK) Funding Opens - Medtech Alert
Monday, October 07, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Musculoskeletal (MSK) Funding Opens | Pharmtech Focus

August 16 2021

Musculoskeletal (MSK) Funding Opens

Funding has been created to support Integrated Care Systems (ICSs) who have an active interest in introducing or scaling up digital innovations within their musculoskeletal (MSK) pathway and have already done some thinking in this area.

Building on the recent launch of the MSK digital playbook, we are looking for a number of ICSs to join us on the ‘Digital Innovations for Musculoskeletal Health’ project. £1m worth of funding is available for ICSs to purchase and implement technology. Applicants can apply for up to £200,000.

Applications from interested ICSs can be submitted between 12 August to 17 September 2021.

Get involved and submit your application

The application form for the opportunity to receive MSK funding is available as a document that you can download and complete (ODT, 85 KB).

Once completed all forms must be returned by email to innovation.offers@nhsx.nhs.uk by 17 September 2021 and include ‘Musculoskeletal – Adoption Fund Application – insert your ICS name’ in the subject line.

If you have any queries prior to submission, please email innovation.offers@nhsx.nhs.uk and include the same process as above in the subject line.

Please ensure you have read the guidance criteria below to help prepare your application. 

Companies In This Post

NHS | Pharmtech Focus

NHS
  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more
More On